Related Experiment Video
Updated: Feb 15, 2026

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
Scutellarin ameliorates nonalcoholic fatty liver disease through the PPARγ/PGC-1α-Nrf2 pathway
Xiaoxue Zhang1, Renpeng Ji1, Huijun Sun1
1a College of Pharmacy , Dalian Medical University , Dalian , China.
Abstract:
Nonalcoholic fatty liver disease (NAFLD) is characterised by excessive accumulation of hepatic lipids and oxidative injury of hepatocytes. Scutellarin is a flavonoid glycoside having antioxidative stress activity. Our current study aims to investigate the molecular mechanism of scutellarin ameliorating NAFLD. Scutellarin treatment was applied to male C57BL/6 mice maintained on a high-fat diet (HFD) and HepG2 cells challenged with oleic acid. The antioxidation biochemical indicators and lipid levels in the liver and cells were detected by kits. Liver pathology was observed by light microscope, Oil Red O staining, and transmission electron microscope (TEM). In addition, quantitative real-time polymerase chain reactions (qRT-PCR) and western blot assays were employed to detect the mRNA and protein levels of various antioxidative-related genes in the presence or absence of peroxisome proliferator-activated receptor gamma (PPARγ); inhibitor GW9662. Our results showed that scutellarin could significantly reduce blood lipid levels and enhance antioxidative capacities in both the models. In addition, scutellarin treatment conspicuously activated PPARγ, peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α), nuclear factor erythroid-2-related factor (Nrf2), haem oxygenase-1 (HO-1), glutathione S-transferase (GST), and NAD(P)H quinone dehydrogenase one (NQO1), while it significantly inhibited nuclear factor kappa B (NF-κB), Kelch-like ECH-associated protein 1 (Keap1) at both the mRNA and protein levels. However, after interfered by GW9662, scutellarin effect was significantly decreased. The experimental data demonstrated that scutellarin showed strong hypolipidaemic, antioxidative, and liver protective activity which could be attributed to its regulating activity in the PPARγ/PGC-1α-Nrf2 signaling pathway.
Insights
Scutellarin, a flavonoid, effectively treats nonalcoholic fatty liver disease (NAFLD) by reducing liver lipids and oxidative stress. It achieves this by activating the PPARγ/PGC-1α-Nrf2 signaling pathway, offering liver protection.
Area of Science:
- Biochemistry
- Pharmacology
- Hepatology
Background:
- Nonalcoholic fatty liver disease (NAFLD) involves excessive liver fat and oxidative damage.
- Scutellarin, a flavonoid glycoside, possesses known antioxidative stress properties.
- Understanding scutellarin's molecular mechanisms in NAFLD is crucial for therapeutic development.
Purpose of the Study:
- To investigate the molecular mechanisms by which scutellarin ameliorates NAFLD.
- To evaluate scutellarin's effects on lipid accumulation and oxidative stress in NAFLD models.
- To elucidate the role of the PPARγ/PGC-1α-Nrf2 signaling pathway in scutellarin's action.
Main Methods:
- Utilized high-fat diet (HFD) induced NAFLD mouse models and oleic acid-challenged HepG2 cells.
- Assessed biochemical indicators, lipid levels, and liver pathology via microscopy and Oil Red O staining.
- Employed qRT-PCR and Western blot to analyze gene and protein expression, including PPARγ inhibition studies.
Main Results:
- Scutellarin significantly reduced blood lipid levels and enhanced antioxidative capacities in both models.
- Scutellarin activated key antioxidative genes/proteins (PPARγ, PGC-1α, Nrf2, HO-1, GST, NQO1) and inhibited inflammatory markers (NF-κB, Keap1).
- Inhibition of PPARγ (using GW9662) diminished scutellarin's beneficial effects, confirming pathway involvement.
Conclusions:
- Scutellarin exhibits significant hypolipidaemic, antioxidative, and hepatoprotective effects against NAFLD.
- These protective activities are mediated through the activation of the PPARγ/PGC-1α-Nrf2 signaling pathway.
- Scutellarin represents a potential therapeutic agent for managing NAFLD.
More Related Videos
09:27Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish
Published on: April 1, 2021
11:08The Use of Gas Chromatography to Analyze Compositional Changes of Fatty Acids in Rat Liver Tissue during Pregnancy
Published on: March 13, 2014
Related Concept Videos
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Overview of Fatty Acid Metabolism
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
Other Glycolytic Pathways
Respiration Pathways